Regeneron reports Q4 2025 earnings with lower EPS and flat revenue, announces new collaboration, and pays dividend.

Regeneron Pharmaceuticals is set to report Q4 2025 earnings on January 30, 2026, with analysts projecting $10.74 EPS, down from $12.07 a year ago, and revenue of $3.79 billion, flat year-over-year. The company announced a global collaboration with Tessera Therapeutics on December 1 to develop TSRA-196. Analysts have raised price targets, with Evercore ISI leading at $875. Regeneron’s stock closed at $749.44, down 0.2%, and the company is scheduled to pay a $0.09 dividend on the same day.